ORTEXORTEX News
Live short interest, options flow, and signals — free on ORTEX.Sign up free →
Market Commentary

Chips, Nukes, and Oil Glut Define a Busy Thursday

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 1 min read

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Semiconductors Back in the Spotlight

Super Micro Computer surged Thursday, topping the high-impact news lists across multiple sources. The server maker joins a broader chip rally that has been building all week. MACOM Technology Solutions was featured live on CNBC as one of the market's best stocks. Both names reflect continued appetite for AI infrastructure plays.

Micron (MU) remains the week's centrepiece. Rosenblatt doubled its price target to $1,200 and upgraded to Buy. Goldman Sachs also lifted its target on Jabil to $482 today, adding a second bullish voice to the contract manufacturer. Jabil's short interest is a minimal 2.8% of free float — bears are staying away.

Nuclear Fuel Heats Up

Centrus Energy climbed today after signing a nuclear fuel supply deal with Oklo. The agreement signals momentum in the small modular reactor space. Energy investors are watching the nuclear supply chain closely as power demand from AI data centres accelerates.

Oil: From Shortage to Glut

The FT flagged a sharp turn in the oil narrative. Fears of $200 oil and summer shortages have faded fast. The market is now focused on a looming supply glut. The Strait of Hormuz reopened after the US-Iran ceasefire, allowing tankers to resume normal routes. AB Volvo affiliate Westport Fuel Systems also moved today on related energy sector flows.

Bears Pile Into Small Caps

Short sellers are targeting battleground names. SharonAI (SHAZ) saw short interest jump 38 points this week to 50.7% of free float. Wolfspeed remains the most extreme case — short interest tops 100% of free float with zero availability. Summit Therapeutics (SMMT) bucks the trend. Its CEO bought $50M of shares this week, a rare signal of insider confidence in the biotech sector.

Stocks in this article

How this article was generated

Generated
18 Jun 2026, 16:52
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowORTEX Alpha signalsORTEX Alpha signalsAnalyst consensus

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.